The Future of Breast Cancer Surgery: From Scalpel-First to Biology-Driven Care
The landscape of breast cancer treatment is undergoing a dramatic shift. For decades, surgery was often the first line of defense – remove the tumor, then address the rest. Now, a biology-driven strategy is taking hold, prioritizing systemic treatments before surgery, and even questioning the necessity of surgery in certain cases. This evolution is fueled by advancements in neoadjuvant therapies, minimal residual disease (MRD) monitoring, and a deeper understanding of the disease at a molecular level.
Molecular Interception: Detecting Cancer Before Symptoms Appear
A key concept driving this change is “molecular interception,” the ability to detect cancer DNA fragments (ctDNA) in the blood long before traditional symptoms manifest. This allows clinicians to move away from calendar-based treatment schedules and towards biological monitoring, tailoring therapy to the individual patient’s response. As Patrick Borgen, MD, of Maimonides Medical Center, explains, this shift enables surgical de-escalation and reduces toxicity.
Neoadjuvant Therapies: Treating the Whole Body First
Neoadjuvant treatments – chemotherapy, endocrine therapy, and increasingly, advanced antibody-drug conjugates (ADCs) and checkpoint inhibitors – are becoming the standard of care for many patients. This approach addresses the entire body, targeting microscopic disease that may have already spread. Previously, these powerful therapies were often reserved for later stages of care. The sequencing of treatments is now critical; surgery first can sometimes limit access to these advanced therapies.
The “Watch and Wait” Protocol: A Paradigm Shift?
The success of neoadjuvant therapies raises a crucial question: what happens when a patient achieves a complete response – the tumor disappears on imaging? The “Watch and Wait” protocol, also known as active surveillance, is gaining traction. However, determining whether a complete response on imaging truly equates to a pathological complete response remains a challenge. While MRI with enhancement is currently the best imaging option, it’s not foolproof.
Researchers are exploring the use of multiple core biopsies to assess for residual disease, but this is an invasive procedure. Some experts, like Henry Kuerer, MD, from MD Anderson Cancer Center, are advocating for proceeding directly to radiation therapy after a complete response on imaging, potentially eliminating the need for surgery altogether. However, this approach isn’t yet widely adopted, as radiation response can vary.
MRD and ctDNA: The Future of Personalized Treatment
Monitoring for minimal residual disease (MRD) using ctDNA is arguably the most exciting development in breast cancer treatment. Measuring DNA fragments in the blood provides a real-time assessment of a patient’s response to therapy. While the technology has advanced rapidly, interpreting and acting on the data is still evolving. Trials are underway to determine the optimal timing and application of MRD and ctDNA testing.
This technology is shifting the focus from treating patients based on risk to treating them based on their individual biology. Treatment courses, traditionally dictated by a calendar, may be shortened or even avoided altogether based on ctDNA results. For example, the need for extended hormone ablative therapy or CDK4/6 inhibitors in estrogen receptor-positive disease could be reassessed.
Addressing Healthcare Disparities: Hub-and-Spoke Models
Access to advanced testing and treatment remains a significant challenge, particularly in underserved communities. Even in a global financial hub like Brooklyn, New York, sophisticated oncologic care isn’t universally available. Dr. Borgen advocates for hub-and-spoke models, where patients from smaller hospitals are referred to centers of excellence for specialized testing and treatment. This ensures that biology, not geography, dictates a patient’s survival.
Emerging Technologies: Fluorescence-Guided Surgery
While promising, technologies like fluorescence-guided surgery, which help surgeons identify occult nodes and positive margins in real-time, are not yet standard practice. Cost and payer mix are significant barriers to widespread adoption. However, these technologies show particular promise in other surgical fields, such as brain tumor resection.
Frequently Asked Questions
Q: What is molecular interception?
A: It’s the detection of cancer DNA fragments in the blood before symptoms appear, allowing for earlier and more targeted treatment.
Q: What are ADCs?
A: Antibody-drug conjugates are advanced therapies that combine the targeting ability of antibodies with the cell-killing power of chemotherapy drugs.
Q: What is the “Watch and Wait” protocol?
A: It’s an approach where surgery is delayed or avoided in patients who achieve a complete response to neoadjuvant therapy.
Q: What is MRD?
A: Minimal residual disease refers to the small number of cancer cells that may remain after treatment. Monitoring for MRD can help predict recurrence.
Q: How will ctDNA impact surgery?
A: A negative ctDNA result may eventually lead to omitting standard-of-care lymphadenectomy in certain disease states, de-escalating the surgical intervention.
Pro Tip: Discuss all treatment options, including clinical trials, with your oncologist to make informed decisions about your care.
Did you know? The COMET trial is investigating whether omitting surgery in patients with low-risk DCIS is a viable option.
Aim for to learn more about the latest advancements in breast cancer treatment? Explore our other articles or subscribe to our newsletter for regular updates.
